Cataract Surgery in Elderly Subjects with Heterozygous Familial Hypercholesterolemia in Prolonged Treatment with Statins
Marco-Benedí, Victoria (Universidad de Zaragoza. Departamento de Medicina, Psiquiatría y Dermatología)
Laclaustra, Martín (Universidad de Zaragoza. Departamento de Medicina, Psiquiatría y Dermatología)
Sánchez-Hernández, Rosa M. (Hospital Universitario Insular de Gran Canaria)
Ortega, Emilio (Hospital Clínic i Provincial de Barcelona)
Pedro-Botet, Juan (Hospital del Mar (Barcelona, Catalunya))
Puzo, Jose (Hospital San Jorge)
Civeira, Fernando (Universidad de Zaragoza. Departamento de Medicina, Psiquiatría y Dermatología)
Universitat Autònoma de Barcelona

Fecha:	2021
Resumen:	Background: Cataracts are the main cause of blindness and represent one fifth of visual problems worldwide. It is still unknown whether prolonged statin treatment favors the development of cataracts. We aimed to ascertain the prevalence of cataract surgery in elderly subjects with genetically diagnosed heterozygous familial hypercholesterolemia (HeFH) receiving statin treatment for ≥5 years, and compare this with controls. Methods: This is an observational, multicenter, case-control study from five lipid clinics in Spain. We collected data with the following inclusion criteria: age ≥65 years, LDL cholesterol levels ≥220 mg/dL without lipid-lowering drugs, a pathogenic mutation in a candidate gene for HeFH (LDLR, APOB, or PCSK9) and statin treatment for ≥5 years. Controls were selected from relatives of HeFH patients without hypercholesterolemia. Linear and logistic regressions based on generalized linear models and generalized estimating equations (GEE) were used. Cataract surgery was used as a proxy for cataract development. Results: We analyzed 205 subjects, 112 HeFH, and 93 controls, with a mean age of 71. 8 (6. 5) and 70. 0 (7. 3) years, respectively. HeFH subjects presented no difference in clinical characteristics, including smoking, hypertension, and type 2 diabetes mellitus, compared with controls. The mean duration of lipid-lowering treatment in HeFH was 22. 5 (8. 7) years. Cataract surgery prevalence was not significantly different between cases and controls. The presence of cataracts was associated neither with LDLc nor with the length of the statin therapy. Conclusion: In the present study, HeFH was not a risk factor for cataract surgery and prolonged statin treatment did not favor it either. These findings suggest that statin treatment is not related with cataracts.
Ayudas:	Instituto de Salud Carlos III PI19/00694
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Cataracts ; Heterozygous familial hypercholesterolemia ; Statins ; Lipid-lowering treatment
Publicado en:	Journal of clinical medicine, Vol. 10 (august 2021) , ISSN 2077-0383

DOI: 10.3390/jcm10163494
PMID: 34441790

5 p, 230.8 KB

El registro aparece en las colecciones:
Artículos > Artículos de investigación
Artículos > Artículos publicados